On October 9, GENSCRIPT BIO fell 3.29% in regular trading, trading at 39.36 HKD/share, with Turnover of 559 million HKD. The stock extended weakness following a sharp drop in overnight U.S. pharmaceutical stocks after Allist Pharmaceuticals announced the failure of its global Phase III trial for furmonertinib, dragging sentiment across Hong Kong's pharmaceutical and biotech sectors.

GENSCRIPT BIO, a leading AIDD concept stock, has faced sustained pressure after a nearly 270% cumulative gain from early July to October 6, prompting some institutions to take profits at high levels. FMR LLC increased its stake on October 2 at an average price of 43.2187 HKD per share, raising its long position to 6.01%. The company provides life science research products and services, covering life science services, biologics development, industrial synthetic biology products, and cell therapy segments.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)